Driving and Commuting

first_imgNAS Fallon is about 6 miles southeast of Fallon. The main highways through the town are U.S. highways 50 and 95. Both provide easy access to the air station. Simply follow the signs to NAS Fallon off the main roads. Interstate 80 is about 30 miles from Fallon and is accessible from U.S. 95 or Alternate 50. Interstate 80 also leads to Reno, 64 miles to the west.The Nevada Department of Transportation offers driving tips and road condition information at www.nevadadot.com. The department provides updates about incidents on specified routes at www.nvroads.com or by dialing 511 or 877-687-3237.Nevada Department of Public Safety555 Wright WayCarson City, NV 89711 775-684-4808www.dps.nv.gov Nevada Department of Motor Vehicles973 W. Williams St.Fallon, NV 89406 877-368-7828www.dmvnv.com The Nevada Department of Motor Vehicles issues driver’s licenses, identification cards, license plates and vehicle registration and provides other driving-related services. Find many of the required forms and general information at www.dmvnv.com/dmvforms.htm.Driver’s LicensesNevada residents who are stationed in Nevada are subject to the same licensing and vehicle registration requirements as non-military. Driver licenses must be renewed before expiration. Nevada does not grant automatic extensions to military members, spouses or dependents. However, active-duty members of the military, federal employees and their spouses and dependents may renew by mail continually.It is recommended that you renew your driver license in person at a DMV office while you are in Nevada. You may renew at any time. You do not have to wait for the expiration date. You may renew at any DMV office regardless of your city or county of residence.The state spells out what is required for licensing and insurance in the Nevada Driver’s Handbook, which can be downloaded at www.dmvnv.com/pdfforms/dlbook.pdf.Distracted DrivingNevada prohibits drivers from talking or texting on a handheld cellphone or similar device while operating a motor vehicle, with fines of up to $250 for violations. The Department of Transportation warns that not only is cellphone use while driving banned in Nevada, but you are four times more likely to crash when driving while talking on a cellphone.Vehicle RegistrationApplications associated with driving and vehicle registration are available online at www.dmvnv.com/dmvforms.htm, including DMV forms, requests for driving records and more.Nevada Department of Transportationwww.nevadadot.com Visit the Nevada Department of Transportation website for interactive maps, information about road closures and travel advisories, and to view live traffic cameras.last_img read more

Vermont AG: New Fed rules confuse maple labeling

first_imgVermont Business Magazine Flanked by maple producers at a Vermont sugarbush in Richmond, Attorney General TJ Donovan called on the federal government to amend its proposed guidance on a rule that would require maple and honey producers to declare “added sugar” content on their labels – even for 100% pure single-ingredient products like maple and honey. Donovan said single-ingredient producers should be exempt, or have other options, when the new rule takes effect. And, he unveiled a new webpage that allows Vermonters to comment on the proposed rule and guidance.“Today, we’re calling on the FDA to listen to Vermonters,” said Donovan. “I support clear and transparent labeling, and I support common sense. That is why I stand with Vermont’s sugarmakers to ask the FDA to amend its guidance so that consumers are not led to believe that anything is added to their 100% pure Vermont maple or honey products.”The Attorney General sent a letter(link is external) to FDA Commissioner Scott Gottlieb requesting the proposed guidance for maple, honey and certain cranberry products to include one or more of the following allowances:Exempt single-ingredient sugars like maple and honey; and/orAllow single-ingredient sugars like maple and honey to simply declare the amount of “total sugar” instead of using the term “added sugar”; and/orAllow single ingredient sugars like maple and honey to declare “0” or “N/A” (“not applicable”) in response to the “added sugar” labeling requirement.Local sugarmakers turned out in support of the Attorney General’s initiative. “Sugarmakers all over Vermont work hard every spring to produce 100% pure maple syrup,” said Roger Brown of Slopeside Syrup, who hosted the Attorney General at its sugarbush in Richmond. “The idea that we would ‘add sugar’ to our syrup is, frankly, offensive,” he said. “Sugarmakers rely on clear labeling to underscore the purity of pure maple syrup as compared to knock-off imitations…  Labeling mandated by the FDA implying adulteration would be an unnecessary disaster.  Cheap, ubiquitous, highly processed corn syrup is an ongoing public health crisis.  Pure maple syrup is not,” said Brown.Donovan also announced that his office has created a new webpage where Vermonters can go to comment on the proposed federal rules at: https://www.uvm.edu/consumer/100-pure-maple-and-democracy(link is external).  “The only thing sweeter than 100% pure maple syrup is democracy,” said Donovan. “I encourage Vermonters to contact the FDA and tell them 100% pure means just that: nothing added.”“Vermonters have stood behind maple for generations and sugarmakers need their support again,” said Brown. “Please tell the FDA what every Vermonter already knows – pure maple syrup has no added sugar.”Donovan also invited FDA Commissioner Scott Gottlieb to Vermont to meet local sugarmakers and sample Vermont’s 100% pure maple and honey products.Source: Vermont AG 6.4.2018last_img read more

Mission prepares to take over animal control services for former NEACC cities

first_imgNEAAC’s operations are currently headquartered out of Mission’s facilities.Mission has agreed to begin contracts with five neighboring cities to provide them animal control services.In the wake of the dissolution of the Northeast Animal Control Commission earlier this year, Mission plans to provide animal control services to the cities of Fairway, Mission Woods, Roeland Park, Westwood and Westwood Hills. Those year-long contracts begin Jan. 1.City administrator Laura Smith, who presented the prepared contracts for the Mission councilmembers during their finance and administration committee meeting Dec. 12, had indicated that Westwood Hills planned to participate in a contractual agreement. That agreement came up for approval in time for the council meeting Dec. 19.Mission has already taken steps to hire two community service officers for the Mission Police Department; these two positions will be dedicated to animal control for Mission and the other cities and will also handle non-essential police functions such as parking complaints, traffic control for accidents and walk-in reports.Councilmember Hillary Parker Thomas at the committee meeting had asked how the two civilian officers will enforce animal control codes for six different cities. Smith said the officers will be required to enforce the city code for each individual city.“One of the provisions that you see, it asks that if (the cities) make changes to their animal control ordinances, that they advise us so that we can certainly keep up with those changes,” Smith told the council Dec. 12.NEACC has provided animal control services to participating northeast Johnson County cities for 35 years and will dissolve after the end of this year. The commission’s decision in May to disband follows nearly four years of discussion over concerns that the joint program for animal control services no longer makes financial sense for participants.There was no public comment or discussion from council.last_img read more

ASP Scan (Weekly) for Oct 05, 2018

first_imgDe-colonization of therapy dogs lessens risk of MRSA spread, study findsA pilot study conducted by researchers at Johns Hopkins has found that using a special antiseptic shampoo and wipes to decolonize therapy dogs before and between visits with young cancer patients can reduce the transmission of methicillin-resistant Staphylococcus aureus (MRSA). The findings were presented today at IDWeek 2018.In the study, the investigators sampled 45 cancer patients and four therapy dogs at Johns Hopkins Bloomberg Children’s Hospital for the presence of MRSA before and after 13 therapy dog visits. Seven of those visits were control visits, in which the dogs were not decolonized; in the six intervention visits, the dogs were bathed with a chlorhexidine-based shampoo prior to visiting patients and were cleaned with chlorhexidine wipes between patient visits.The hypothesis was that the dogs could be a vector for transmitting MRSA between patients. MRSA carriage in cancer patients is a concern because their weakened immune systems put them at greater risk of infection.The investigators found that 4 of the 45 patients became MRSA carriers after the control visits, as did three of the dogs. Patients who interacted more closely with the dogs were six times more likely to be colonized with MRSA than those who didn’t interact closely.But during the six interventions visits, only one of the patients and two of the dogs became colonized, and the risk for MRSA transmission among patients who interacted closely with the dogs was significantly reduced. Overall, regardless of the level of interaction, the intervention reduced the risk of MRSA colonization in patients by 90%.”While there was still a risk of children for children being involved in these therapy visits, because of their direct contact with other patients or other environments, it essentially removed the dog from the equation, which overall increased the safety of the visit,” lead study author Kathryn Dalton, VDM, MPH, of Johns Hopkins Bloomberg School of Public Health, said at a press conference.Dalton said they also observed many patient benefits from therapy-dog visits, including decreased stress levels and fewer reports of anxiety and pain. Because of the positive results, Dalton and her colleagues have received additional funding for a larger study involving multiple hospitals.IDWeek 2018 abstract #160 Gene study supports multiple Candida auris introductions into USWhole-genome sequencing of Candida auris isolates from patients in 10 US states suggests that the fungal strain came from four different global regions, reflecting multiple introductions into the country. A team led by researchers from the US Centers for Disease Control and Prevention’s mycotic diseases branch reported its findings yesterday in The Lancet Infectious Diseases.The group examined isolates collected from May 2013 through August 2017 from 133 cases, 73 of them clinical specimens and 60 screening samples. Of the clinical isolates, sequencing found that 90% were related to South Asian, 7% to South American, 1% to African, and 1% to East Asian isolates. Most isolates were from New York and New Jersey, and though they were related to South Asian C auris strains, most were genetically distinct.Genetic comparison suggested that only 5 clinical case-patients (7%) likely contracted the fungus during healthcare exposure abroad. Genetic diversity within a patient was similar to that seen in facilities during outbreaks.The investigators concluded that the findings shed light on fungus introduction and how it can occur following travel. They added that the genetic diversity among isolates from patients, states, and facilities adds evidence of local and ongoing transmission.In a commentary in the same issue, Jacques Meis, MD, PhD, a mycologist from the Netherlands, and Anuradha Chawdhary, MD, PhD, a mycologist from India, wrote that the findings confirm earlier work that the global C auris population consists of four different clades that harbor nearly identical strains within each clade. They said the US cases don’t represent a fifth clade but instead represent several introductions into the US healthcare system. They note that the travel-related cases identified in the study weren’t the outbreak index cases, suggesting previous unrecognized presence and transmission of the fungus.A major unanswered question is the reservoir for C auris outside hospitals, they note. Though the drivers of the spread are elusive, the two wrote that demographics, extensive fluconazole use in intensive care units, poor infection control, international travel, and medical tourism likely play a role in ongoing outbreaks.”The stringent recognition of the problem and simultaneous implementation of precautions to prevent the spread of C auris among patients should be taken as seriously as in bacterial pathogens,” they wrote.Oct 4 Lancet Infect Dis abstractOct 4 Lancet Infect Dis commentary Study finds stewardship intervention early in hospital stay may pay offA single-center study in Japan determined that an intervention from an antimicrobial stewardship team earlier in a hospital stay was associated with significantly fewer antibiotics prescribed, a lower incidence of antimicrobial resistance, and reduced costs, according to a study yesterday in the International Journal of Infectious Diseases.The retrospective study was conducted at Fukuoka University Hospital from April 2013 through March 2016. The researchers compared data among three study periods (SPs): SP1 (patients receiving antibiotics against MRSA and carbapenems for 14 or more days), SP2 (patients receiving specific antimicrobials for 14 or days), and SP3 (patients receiving specific antimicrobials regardless of the duration of treatment). The average timing of stewardship interventions ranged from 15.5 days after hospital admission in SP1 to 4.2 days in SP3.The investigators determined that the antimicrobial use density of carbapenems and piperacillin-tazobactam decreased significantly (SP2 vs. SP3, P < 0.05), and the costs of specific antimicrobials decreased (SP1, $1,080,000; SP2, $944,000; SP3, $763,000). The rates of carbapenem resistance among Pseudomonas aeruginosa isolates showed a significant reduction from 16.2% in SP2 to 8.7% in SP3 (P < 0.05). The mortality rate and length of stay did not change during the study period.Oct 4 Int J Infect Dis abstract Topical phage treatment shows potential, weaknesses, in small clinical trialOriginally published by CIDRAP News Oct 4The results of a small clinical trial in France show that a topical treatment containing a cocktail of bacteriophages successfully reduced bacterial burden in patients with infected burn wounds, but at a significantly slower rate than standard of care. The findings appeared yesterday in The Lancet Infectious Diseases.In the randomized phase 1/2 PhagoBurn trial—the first randomized controlled trial to investigate phage therapy—25 patients with a confirmed burn wound that was clinically infected with Pseudomonas aeruginosa were recruited from nine hospitals in France and Belgium. The participants were randomly assigned 1:1 to receive topical treatment for 7 days with a cocktail of 12 natural lytic anti-P aeruginosa bacteriophages collected from hospital sewer water (PP1131) or standard of care (1% sulfadiazine silver emulsion cream). The primary end point was median time to sustained reduction in bacterial burden in two quadrants via a four-quadrant method, assessed by use of daily swabs in all participants.Of the patients—recruited from Jul 22, 2015, to Jan 2, 2017—13 received  phage therapy and 12 received standard of care. The primary end point was reached in a median of 144 hours in the PP1131 group versus a median of 47 hours in the standard-of-care group (hazard ratio, 0.29; 95% confidence interval, 0.10 to 0.79; P = 0.018). In the PP1131 group, 6 of the 12 analyzable participants (50%) had a maximal bacterial burden versus 2 of 13 (15%) in the standard-of-care group. Adverse events were higher in the standard-of-care group (7/13, 54%) than in the PP1131 group (3/13, 23%). A follow-up study of bacteria isolated from patients whose PP1131 treatment failed showed resistance to low-phage doses.Recruitment was stopped on Jan 2, 2017, because of concerns about patient exposure to insufficient phage concentration. On Mar 20, 2017, a data and safety monitoring board recommended stopping the trial because of the insufficient efficacy of PP1131.The researchers say, however, that the clinically relevant reduction in bacterial burden observed in the group treated with the phage cocktail, and the smaller number of adverse events compared with standard of care, illustrate the potential of phage therapy."Although the effect was slower than in the control group, we found that our phage cocktail reduced bacterial burden in the infected wounds of patients with burns, one of the most difficult populations to treat, and something that, to our knowledge, has never been achieved in a human trial before," they write.Oct 3 Lancet Infect Dis abstract Study highlights high levels of inappropriate antibiotic prescribing in ChinaOriginally published by CIDRAP News Oct 4Chinese researchers employed actors pretending to be patients with one of three conditions that didn't require antibiotics and found that in 42% of 526 rural primary care encounters, physicians inappropriately prescribed the drugs anyway, according to a study today in the Journal of Antimicrobial Chemotherapy.The study took place in village clinics and township health centers, the two lower tiers of China's three-tiered rural health system, in three geographically dispersed regions. The "patients" recruited for the study were trained to present cases of pulmonary tuberculosis, viral gastroenteritis, or unstable angina. The investigators also provided primary care providers with clinical vignettes to assess antibiotic prescribing habits.The researchers found that providers inappropriately prescribed antibiotics in 221 of 526 patient visits, or 42% of the time. And compared with patient interactions, prescription rates were 29% lower in matching clinical vignettes (42% vs. 30%), suggesting practices don't always follow theoretical knowledge. Compared with vignettes assessing diagnostic and therapeutic knowledge jointly, prescribing rates were 67% lower in vignettes with the diagnosis revealed.The authors conclude, "While a large proportion of overprescription may be due to factors such as financial incentives tied to drug sales and perceived patient demand, our findings suggest that deficits in diagnostic knowledge are a major driver of unnecessary antibiotic prescriptions."Oct 4 J Antimicrob Chemother abstract Point-of-care flu tests don't lower antibiotic prescribing, study findsOriginally published by CIDRAP News Oct 4A meta-analysis today in Clinical Infectious Diseases of 13 studies involving point-of-care tests (POCTs) for influenza finds that they had no effect on admissions, return visits, or antibiotic prescribing but were associated with increased antiviral prescribing.UK experts included in their review seven randomized and six non-randomized studies that involved more than 9,000 patients total. Most evidence came from pediatric emergency departments.In randomized trials, POCTs had no effect on admissions, returning for care, or antibiotic prescribing, but they were tied to an increase in prescribing antivirals. In addition, further testing was reduced for full blood counts, blood cultures, and chest x-ray but not for urinalysis. Time in the emergency department was not changed. Fewer non-randomized studies reported these outcomes, with some findings reversed or lessened.The researchers conclude, "Point-of-care testing for influenza influences prescribing and testing decisions, particularly for children in emergency departments."Oct 4 Clin Infect Dis abstract FDA approves new antibiotic for bacterial pneumonia, skin infectionsOriginally published by CIDRAP News Oct 3The US Food and Drug Administration (FDA) yesterday approved Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin-structure infections (ABSSSIs), according to a press release yesterday from drug maker Paratek Pharmaceuticals.Nuzyra is a "modernized" tetracycline that's designed to overcome tetracycline resistance and exhibits activity against gram-positive and gram-negative bacteria, atypicals, and drug-resistant strains. It comes in both intravenous and oral formulations."In the face of ever-increasing antibiotic resistance, the FDA approved Nuzyra with a label having full approval for both CABP and ABSSSI," Paratek president and chief medical officer Evan Loh, MD, said in the press release. "We are excited to bring to physicians an effective, well-tolerated monotherapy option for patients."The approval was based on multiple clinical trials in which Nuzyra was found to be efficacious, safe, and well-tolerated in nearly 2,000 patients. Paratek plans to make the drug available in the first quarter of 2019.Oct 2 Paratek Pharmaceuticals press release Combo antibiotic for CRE infections performs well in phase 3 trialOriginally published by CIDRAP News Oct 2The results of a phase 3 randomized, controlled clinical trial show that monotherapy with the antibiotic/beta-lacatamase inhibitor combination Vabomere (meropenem-vaborbactam) in patients with carbapenem-resistant Enterobacteriaceae (CRE) infections was associated with increased clinical cure, decreased mortality, and reduced kidney toxicity compared with the best available therapy (BAT). The results were published yesterday in Infectious Diseases and Therapy.In the Targeting Antibiotic Non-susceptible Gram-negative Organisms (TANGO) II trial, 77 patients with confirmed CRE infection from 27 hospitals in eight countries were randomized 2:1 to receive meropenem-vaborbactam alone for 7 to 14 days or BAT (mono/combination therapy with polymyxins, aminoglycosides, tigecycline; or ceftazidime-avibactam alone). Forty-seven patients with confirmed CRE infection formed the primary analysis population. Efficacy end points included clinical cure, day-28 all-cause mortality, microbiologic cure, and overall success (clinical cure plus microbiologic eradication). The most common infection types were bacteremia and complicated urinary tract infections (cUTIs).In the primary analysis population, cure rates were 65.6% (21/32) for patients receiving meropenem-vaborbactam and 33.3% (5/15) for BAT patients at end of treatment and 59.4% (19/32) and 26.7% (4/15) at test of cure. Day-28 all-cause mortality was 15.6% (5/32) and 33.3% (5/15) for meropenem-vaborbactam versus BAT, respectively. In the safety population, meropenem-vaborbactam was associated with fewer drug-related adverse events (24% [12/50] vs. 44% [11/25]), fewer serious adverse events (34% [17/50] vs. 44% [11/25]), and fewer kidney-related adverse events (4% [2/50] vs. 24% [6/25]) than BAT was.Exploratory risk-benefit analyses of composite clinical failure or nephrotoxicity also favored meropenem-vaborbactam over BAT, 31.3% (10/32) to 80% (12/15).The authors of the study conclude that the results indicate that meropenem-vaborbactam, which was approved by the US Food and Drug Administration in 2017 for use in cUTI patients based on results from the TANGO I trial, "will be a valuable addition to the antimicrobial armamentarium against CRE pathogens."Oct 1 Infect Dis Ther study  Telemedicine study finds antibiotic Rx linked with shorter encountersOriginally published by CIDRAP News Oct 1Researchers from the Cleveland Clinic have observed that telemedicine encounters in which antibiotics were prescribed for a respiratory tract infection (RTI) were shorter than encounters where a non-antibiotic or nothing were prescribed.In a study today in the Annals of Internal Medicine, the researchers reviewed 13,438 US telemedicine encounters from January 2013 through August 2016 to assess the association between prescription outcome and length of encounters for patients diagnosed as having RTIs, including sinusitis, pharyngitis, and bronchitis. Encounter length was defined as the time the patient was connected to and interacted with the physician. The adjusted difference in encounter length was determined using a mixed-effects linear regression model that controlled for patient characteristics, physician characteristics, and geographic concordance between patient and physician.Physicians prescribed antibiotics in 67% of encounters, non-antibiotics in 13%, and nothing in 20%. The mean unadjusted encounter length was 6.6 minutes when antibiotics were prescribed, 8 minutes when non-antibiotics were prescribed, and 7.5 minutes when nothing was prescribed. In the adjusted model, encounters that resulted in nothing being prescribed were 33 seconds longer than those resulting in antibiotic prescriptions; those resulting in prescription of a non-antibiotic were 1.12 minutes longer than those in which an antibiotic was prescribed.In addition, encounters for sinusitis and pharyngitis were found to be shorter than those for bronchitis and other RTIs, encounters with older patients were longer than those with younger patients, and encounters with physicians in the West took longer than those with physicians in the Northeast. The researchers were not able to determine the appropriateness of antibiotic prescribing.The authors suggest the findings are noteworthy because prescribing non-antibiotics has been suggested as a way to improve patient satisfaction while avoiding unnecessary antibiotics. But the longer time needed to explain why an antibiotic isn't necessary could be an impediment, especially with telemedicine. They conclude, "Because telemedicine encounters are short and physicians are often reimbursed by encounter volume, antibiotic stewardship efforts that lengthen visits even slightly may be challenging to implement."Oct 2 Ann Intern Med abstract FDA approves new antibiotic under limited population pathwayOriginally published by CIDRAP News Oct 1The FDA has approved a new antibiotic for the treatment of lung disease caused by Mycobacterium avium complex (MAC), a nontuberculosis mycobacterium commonly found in water and soil.The agency approved Arikayce (amikacin liposome inhalation suspension) for use in a limited population of patients who don't respond to conventional treatment. It's the first drug to be approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), which was established by Congress as part of the 21st Century Cures Act to streamline development and approval of drugs to treat serious or life-threatening infections in a small population of patients who have no other treatment options."This pathway, advanced by Congress, aims to spur development of drugs targeting infections that lack effective therapies," FDA Commissioner Scott Gottlieb, MD, said in an FDA news release. "We're seeing a lot of early interest among sponsors in using this new pathway, and it's our hope that it'll spur more development and approval of antibacterial drugs for treating serious or life-threatening infections in limited populations of patients with unmet medical needs."The safety and efficacy of Arikayce were demonstrated in a randomized, controlled clinical trial where one group of patients received the drug plus a background multidrug antibacterial regimen, and a second group received the multidrug antibacterial regimen alone. By the sixth month of treatment, 29% of patients who received Arikayce had no growth of mycobacteria in their sputum cultures for 3 consecutive months, compared with 9% of the patients who were not treated with Arikayce.As required for drugs approved under LPAD, labeling for Arikayce will include statements conveying that the drug has been shown to be safe and effective for use only in a limited population of patients. Sep 28 FDA news release Linezolid resistance genes found in cattle, swine enterococciOriginally published by CIDRAP News Oct 1A study today by FDA and US Department of Agriculture (USDA) researchers is reporting the first known identification of linezolid resistance in bacteria from food-producing animals in the United States. The findings appear in the Journal of Antimicrobial Chemotherapy.In an analysis of 500 bacterial isolates from food-animal cecal samples collected by the National Antimicrobial Resistance Monitoring System (NARMS) from 2013 through 2016, the researchers identified three isolates that were non-susceptible to linezolid, an oxazolidinone antibiotic that's used to treat vancomycin-resistant enterococci(VRE) infections in humans but is not used in animals. Two of the isolates were from cattle, including one each of Enterococcus faecium and E faecalis, and one E faecalis isolate was from a swine sample.Whole-genome sequencing to determine the mechanisms underlying the resistant phenotypes revealed that all three isolates carried the linezolid resistance gene optrA, with one also carrying the cfr resistance gene. The genes were present on plasmids in all three isolates, and the E faecium isolate that possessed both optrA and cfr had them both on the same plasmid. In addition, the plasmid in the E faecium isolate also contained genes conferring resistance to aminoglycosides, macrolides, and phenicols.The researchers note that while only three linezolid-resistant isolates were identified, the fact that they came from different sources and were genetically diverse suggests that linezolid-resistance plasmids are not limited to a distinct lineage of Enterococcus, and that resistant strains could independently emerge from different environments, including the food-animal environment. If these strains spread into humans, that could potentially threaten a critical antibiotic in human medicine."Although the presence of linezolid-resistant strains in food animals may not directly increase the risk of limiting the efficacy oxazolidinones in human therapy, people may become exposed to these bacteria through animal contact or contamination of food," the authors of the study write. "Now that we have identified linezolid resistance genes on plasmids that also carry other resistance genes, it remains to be seen whether these genes spread further through co-selection, clonal expansion, or other mechanisms."The authors say investigators will continue to use NARMS to perform surveillance of linezolid resistance among enterococci from food animals and foods to identify any notable trends.Oct 1 J Antimicrob Chemother abstract Study: Drinking more water might prevent urinary tract infectionsOriginally published by CIDRAP News Oct 1Women who drank more water were less likely to get urinary tract infections (UTIs) than controls and may be a way to reduce antibiotics, according to a study today in JAMA Internal Medicine.The study involved 140 women who reported three or more UTIs in the previous year. Half of the women were encouraged to drink 1.5 liters of water daily for 12 months in addition to their normal beverages, and half were not. The women who drank more water saw a 50% reduction in UTIs. The mean number of cystitis (UTI) episodes was 1.7 (95% confidence interval [CI], 1.5-1.8) in the water group, compared with 3.2 (95% CI, 3.0-3.4) in the control group, with a difference in means of 1.5 (95% CI, 1.2-1.8; P < .001), the authors said. Overall, there were 327 cystitis episodes, 111 in the water group and 216 in the control group. The authors concluded by saying that increased water consumption is a useful tool for UTI prevention that limits antibiotic use.In an accompanying editorial, JAMA editor Deborah Grady, MD, PhD, notes that the study was not blinded, and the results were self-reported. She also emphasized that the study was sponsored by Danone, a company that supplied bottled water to study participants.Despite those caveats, Grady said, "The research question is important and the intervention was safe, easy, and effective (and it would be impossible to blind a trial in which drinking water is the intervention)."Oct 1 JAMA Intern Med studyOct 1 JAMA Intern Med editoriallast_img read more

Mobiles’ home

first_imgWould you like to read more?Register for free to finish this article.Sign up now for the following benefits:Four FREE articles of your choice per monthBreaking news, comment and analysis from industry experts as it happensChoose from our portfolio of email newsletters To access this article REGISTER NOWWould you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week.last_img

Letters to the Editor for Tuesday, Feb. 26

first_imgCategories: Letters to the Editor, OpinionAdd these to Trump’s “accomplishments”I would like to add to the 289 Trump accomplishments alluded to in Mr. DeAngelus’ Feb. 17 letter. Oh, where to start. Our national debt is estimated to be $25 trillion by 2021. So much for Republicans’ fiscal constraint. Our children and grandchildren will thank us. Mexico will pay for the wall. I forgot, that won’t happen. The rest of the world looks up to us — not. The tax cut will mostly benefit the middle class. Really? The swamp will be drained. Now that’s a good one. I would like to add a few more to get to an even 300, but the paper might run out of space.James Brodie Schenectady Do more to coordinate social justice effortsThe need for improved educational services for youth and adults indicates social justice coordination among agencies is essential.Recognition of this by SUNY’s University Center for Academic and Workforce Development (UCAWD) has established a network of Educational Opportunity Centers collaborating with state, municipal and county agencies, secondary and post-secondary institutions, community-based organizations, and business and industry in its efforts.Academically and economically underserved students who are at least 16 years old  have accessed traditional classroom learning with applied science or hands-on projects to become skilled workers for businesses.Collaboration among guidance counselors, teachers, teacher assistants, parents and students is essential for the state Board of Regents’ Whole Child Social and Emotional Learning approach to access classroom learning and applied science projects for the students.In our area, the GE Brilliant Career Lab was established through partnership by the GE Foundation, the GE Power, and Schenectady city’s public-school district.The reproduction of that model requires social-justice minded individuals to persuade municipal and school district officials to utilize the State-County Shared Services Initiative to coordinate the federal-state funded 21st Century Community Learning Center program with the UCAWD network for academically and financially underserved youth and adults.Michael McGlynnWatervliet Our area would be the best place for AmazonMr. Bezos, please consider the New York Capital District/Tech Valley as an excellent Amazon HQ2 LIC alternative.1. Believe the governor could make it happen in his backyard with incentives.2. Benefit to the region. Jobs create income which generates tax revenue from 25,000 employees, people have disposable income which creates revenue for local businesses and additional tax revenue, and reduction in government funds required to support unemployment issues.Available real estate for a project of this proportion. Downtown Albany skyscrapers that could be renovated, state office complex, Rensselaer waterfront.3. Quality of life with great healthcare, low crime, great schools, affordable housing, low traffic, increasingly temperate weather, low probability of floods, earthquakes, hurricanes, natural disasters.4. Intellectual talent including established model for technical transformation, already being the No. 1 location in the world for intellectual talent in the field of nanotechnology.Leading technical companies already established here including Global Foundries (recently brought 10,000 jobs), Regeneron (leading pharmaceutical firm growing exponentially), and GE’s Global Research. Access to new talent through leading world class technological universities: RPI, SUNY Polytechnic, SUNY Albany, Albany Law.5. Location: currently 2.5-hour car/train ride to New York City or Boston. Modern, easily accessible international airport. Capital government proximity.6. Recreation: extensive hiking and biking trails, swimming, skiing, fishing, hunting, boating, snowmobiling, parks, clean air/water, active outdoor minded people.Proximity to Adirondack and Catskill Mountains, Saratoga, Lake George, Hudson, Battenkill, and Delaware rivers. Proctor’s off-Broadway plays. Short trip to skiing, Cape Cod, New Jersey Shore, Hampton’s beaches, and Montreal.Michael IzdebskiBethlehemcenter_img More from The Daily Gazette:EDITORIAL: No more extensions on vehicle inspectionsEDITORIAL: Thruway tax unfair to working motoristsHIGH NOTES: PPEs, fighting hunger, backpacks and supplies for kidsEDITORIAL: Make a game plan for voting. Do it now.Foss: Schenectady homeless assistance program Street Soldiers dealing with surge in needlast_img read more

MEECO celebrates 65 years in gas analysis

first_imgSubscribe Get instant access to must-read content today!To access hundreds of features, subscribe today! At a time when the world is forced to go digital more than ever before just to stay connected, discover the in-depth content our subscribers receive every month by subscribing to gasworld.Don’t just stay connected, stay at the forefront – join gasworld and become a subscriber to access all of our must-read content online from just $270.last_img

McDermott, Petrofac join forces to pursue SURF projects

first_imgImage: McDermott McDermott International and Petrofac said they have formed a strategic marketing alliance to pursue deepwater subsea, umbilical, riser and flowline (SURF) projects.The five-year alliance expects to provide oil and gas companies a competitive, integrated solution across a broad range of complex engineer, procure, construct, install (EPCI) subsea projects in deep and ultra-deepwater across the US Gulf of Mexico, Mexico, Brazil, the North Sea, Mediterranean and West Africa, the companies said in a joint statement.Leveraging the complementary capabilities and experience of both companies, the alliance will open up further EPCI opportunities by combining McDermott’s SURF fleet, its new Derrick Lay Vessel DLV 2000 with Petrofac’s JSD 6000 installation vessel, according to the statement.Currently under construction, the JSD 6000 complements McDermott’s vessels, offering functionality for a wide range of ultra-deepwater pipelay, subsea lowering and above surface construction work, through its combined J-lay, S-lay and ultra-heavy lift capabilities.last_img read more

Coronavirus means the certainties of just a few weeks ago are now clouded in doubt

first_imgSUBSCRIBE to access this story SUBSCRIBE for UNLIMITED access to news and premium contentA subscription will provide access to the latest industry news, expert analysis & comment from industry leaders,  data and research – including our popular annual league tables. You will receive:Print/digital issues delivered to your door/inboxUnlimited access to building.co.uk including our archivePrint/digital supplementsNewsletters – unlimited access to the stories behind the headlinesSubscribe now  Get access to premium content subscribe todaylast_img read more

Local singer releases single

first_imgPat McCays new single, Shape Shifting, speaks of grace in the chaos of uncertainty. Singer and songwriter Pat McCay has released the second single off his recently launched EP, Ready. The track, called Shape Shifting, layers subtle melodic vocals and laid-back beats to offer a vivid glimpse into the personal metamorphosis the Kenilworth resident underwent in recent years. “About 10 years ago I was given a book called Power Thoughts; this little book kick-started my process of healing. I began to ‘cultivate the observer’ i.e. I started to acknowledge some of the thoughts that I was unknowingly ‘in reaction’ to. “This, along with many failed attempts to get clean at a host of treatment facilities, finally brought me to a place where I was ready to change my life at the end of 2016,” says McCay.Parts of the journey that brought him to wellness can be heard in the mood and lyrics of the songs on his recent EP, especially Shape Shifting. “It was super rough, but I’m so grateful for my family and friends that supported and helped me on my journey to wellness. I experienced a major shift in the beginning of 2018, and I can honestly say life has been radically different since then,” says McCay. He says one of the skills he learned in recovery was to speak from his own experience instead of dissociating, and that he brought this to his music as well. “When you share truth in your songs, others can see their own experiences echoed in the music and it makes them feel connected. “Pretty much everyone struggles with some form of addiction and in some ways connection is the opposite of addiction. Instead of giving empty advice, I choose to share where I’m at – it’s raw and it’s real.“In a sense the EP addresses some common longings, such as the need to be seen and heard. There are a lot of people out there who are trying to fix the world before they’ve done the work to fix themselves. Personally, I don’t think there’s anything more powerful than truly learning to love what God made – namely yourself. Learning to love others is a natural part of that process.”McCay says Shape Shifting is the track that is most descriptive about his past and also draws attention to the common struggle of feeling out of place, while simultaneously focusing on hope. “Shape Shifting celebrates the fact that in those times that I wasn’t really present, there were people looking after me, watching out for me. Some might call them angels. It’s a song of grace and the realisation that we’ve always been unconditionally loved, both in our mess and in our glory.”Listen to Shape Shifting on Apple Music / iTunes, Spotify, Deezer, YouTube or SoundCloud.last_img read more